About InVivoMAb anti-mouse Vβ8 TCR

The F23.1 monoclonal antibody reacts with the Vβ 8.1, Vβ 8.2, and Vβ 8.3 TCR (V beta 8.1-3 T cell receptors) of mice having the b haplotype of the Tcrb gene complex (e.g., AKR, BALB/c, C3H, C57BL, DBA/1, DBA/2). The TCR is expressed on the surface of T lymphocytes and is responsible for recognizing fragments of antigen as peptides bound to MHC molecules. When the TCR engages with antigenic peptide and MHC the T lymphocyte is activated through signal transduction. The F23.1 antibody has been shown to activate Vβ 8 TCR-expressing T lymphocytes, as well as block cytolysis mediated by Vβ 8 TCR-expressing cytotoxic T lymphocytes. Additionally, in vivo treatment of neonatal mice with the F23.1 antibody can arrest intrathymic maturation of Vβ 8 TCR-expressing T cells.